These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37827343)

  • 1. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
    Qiao L; Dong C; Jia W; Ma B
    Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.
    Ganesan K; Xu C; Wu J; Du B; Liu Q; Sui Y; Song C; Zhang J; Tang H; Chen J
    Sci China Life Sci; 2024 Sep; 67(9):1849-1866. PubMed ID: 38900236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naa20, the catalytic subunit of NatB complex, contributes to hepatocellular carcinoma by regulating the LKB1-AMPK-mTOR axis.
    Jung TY; Ryu JE; Jang MM; Lee SY; Jin GR; Kim CW; Lee CY; Kim H; Kim E; Park S; Lee S; Lee C; Kim W; Kim T; Lee SY; Ju BG; Kim HS
    Exp Mol Med; 2020 Nov; 52(11):1831-1844. PubMed ID: 33219302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsa_circ_0001756 promotes ovarian cancer progression through regulating IGF2BP2-mediated RAB5A expression and the EGFR/MAPK signaling pathway.
    Ji J; Li C; Wang J; Wang L; Huang H; Li Y; Fang J
    Cell Cycle; 2022 Apr; 21(7):685-696. PubMed ID: 35113003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
    Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
    Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
    Cheng W; Liu D; Guo M; Li H; Wang Q
    Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
    Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
    Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.
    Fang T; Hu S; Song X; Wang J; Zuo R; Yun S; Jiang S; Guo D
    Breast Cancer Res Treat; 2024 Sep; 207(2):435-451. PubMed ID: 38958784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT5DC2 knockdown suppresses progression, glycolysis, and neuropathic pain in triple-negative breast cancer by blocking the EGFR pathway.
    Sang R; Yu X; Xia H; Qian X; Yong J; Xu Y; Sun Y; Yao Y; Zhou J; Zhuo S
    Mol Carcinog; 2024 Apr; 63(4):785-796. PubMed ID: 38289126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells.
    Jin X; Yang S; Lu X; Chen X; Dai W
    Breast Cancer Res; 2024 Jun; 26(1):92. PubMed ID: 38840145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAB5A in triple-negative breast cancer: a critical role in macrophage reshaping in an exosomal miR-21-dependent manner.
    Qiao L; Dong C; Jia W; Sun G
    Endocr Relat Cancer; 2024 May; 31(5):. PubMed ID: 38470169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
    Ding L; Xie Z
    Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
    Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
    Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.